{
  "@context": {
    "biotools": "https://bio.tools/ontology/",
    "bsc": "http://bioschemas.org/",
    "edam": "http://edamontology.org/",
    "rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
    "rdfs": "http://www.w3.org/2000/01/rdf-schema#",
    "sc": "http://schema.org/",
    "xsd": "http://www.w3.org/2001/XMLSchema#"
  },
  "@graph": [
    {
      "@id": "https://doi.org/10.1007/S10928-019-09662-3",
      "@type": "sc:CreativeWork"
    },
    {
      "@id": "https://bio.tools/E14",
      "@type": "sc:SoftwareApplication",
      "sc:applicationSubCategory": [
        {
          "@id": "edam:topic_0202"
        },
        {
          "@id": "edam:topic_3377"
        },
        {
          "@id": "edam:topic_3379"
        },
        {
          "@id": "edam:topic_3375"
        }
      ],
      "sc:citation": [
        "pubmed:31667657",
        {
          "@id": "https://doi.org/10.1007/S10928-019-09662-3"
        }
      ],
      "sc:description": "Cardiac risk assessment based on early Phase I data and PK-QTc analysis is concordant with the outcome of thorough QTc trials.\n\nCardiac safety assessment is a key regulatory requirement for almost all new drugs. Until recently, one evaluation aspect was via a specifically designated, expensive, and resource intensive thorough QTc study, and a by-time-point analysis using an intersection-union test (IUT). ICH E14 Q&A (R3) (http: www.ich.org fileadmin Public_Web_Site ICH_Products Guidelines Efficacy E14 E14_Q_As_R3__Step4.pdf) allows for analysis of the PK-QTc relationship using early Phase I data to assess QTc liability.\n\n||| CORRECT NAME OF TOOL COULD ALSO BE 'ICH', 'QTc', 'thorough QTc', 'Cardiac risk assessment based early Phase I data PK-QTc analysis concordant outcome thorough QTc ...'",
      "sc:featureList": [
        {
          "@id": "edam:operation_3435"
        },
        {
          "@id": "edam:operation_3454"
        }
      ],
      "sc:name": "E14",
      "sc:url": "http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Q_As_R3__Step4.pdf"
    }
  ]
}